Argus retinal prosthesis

<p>Argus retinal prosthesis, also known as a bionic eye, is an electronic <a href="/facts/Retinal_implant/NtxRHaSQ">retinal implant</a> manufactured by the <a href="/facts/United_States/P0sCdLe5">American</a> company Second Sight Medical Products. It is used as a <a href="/facts/Visual_prosthesis/xxcKlDK9">visual prosthesis</a> to improve the vision of people with severe cases of <a href="/facts/Retinitis_pigmentosa/eIbETPzm">retinitis pigmentosa</a>. The Argus II version of the system was approved for marketing in the <a href="/facts/European_Union/6GYcR8qM">European Union</a> in March 2011, and it received approval in the US in February 2013 under a <a href="/facts/Humanitarian_device_exemption/RKdr4URk">humanitarian device exemption</a>.  The Argus II system costs about US$150,000, excluding the cost of the implantation surgery and training to learn to use the device. Second Sight had its IPO in 2014 and was listed on <a href="/facts/Nasdaq/C6GlcQcB">Nasdaq</a>.
</p><p>Production and development of the prosthesis was discontinued in 2020, but taken over by the company Cortigent in 2023.
</p>

Argus retinal prosthesis open-in-new

Argus retinal prosthesis